Earlier this week, Virginia Kaklamani, MD, leader of the @UTHealthSAMDAnderson breast cancer program and co-director of the @SABreastCancerSymposium, presented the Phase III results of EMERALD, a clinical trial evaluating a novel oral drug therapy (Elacestrant) for metastatic ER-positive/HER2-negative (ER+/HER2-) breast cancer. The trial has shown to date that the oral drug improves outcomes in patients compared with standard-of-care endocrine therapy and is currently being evaluated by the U.S. Food and Drug Administration for approval. #SABCS22

свернуть